Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
Palisade Bio reported Q1 2026 results, with research and development expenses climbing to $6.4 million, up from $1.0 million a year earlier. The rise reflects higher staffing, chemistry, manufacturing, and clinical trial costs for its lead candidate PALI-2108. The company also disclosed encouraging Phase 1b data for PALI-2108 in fibrostenotic Crohn’s disease and plans IND submissions for Phase 2 trials in ulcerative colitis and Crohn’s disease later this year. General and administrative expenses increased to $4.4 million, driven by professional fees and share‑based compensation.
#392 - Genetic Testing: When It's Valuable, How to Choose the Right Test, and What to Do with the Results
In this episode, host Peter Atiyah demystifies genetic testing by outlining when it truly adds value, how to select the appropriate test, and how to act on the results. He explains that most genetic information is probabilistic, highlights the limits...
Heart Valve Surgery Recovery: What To Expect
Heart valve replacement—either surgical (SAVR) or transcatheter (TAVR)—offers a high success rate but requires a structured recovery. SAVR patients typically spend 3‑7 days in the hospital and need four to six weeks for initial healing, while TAVR patients may go...
Here’s When (and Why) You Might Need Surgery or TAVR for Severe Aortic Stenosis
Severe aortic stenosis is treated by replacing the narrowed valve, either through surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR). Physicians base the decision on three criteria: valve area under 1 cm², heart’s functional response (ejection fraction and...
This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’
Duracyte, a Rice‑University spin‑out, is developing an implantable "cell factory" that produces therapeutic proteins inside patients, eliminating the need for traditional biologic manufacturing and injection pens. The capsule‑sized device houses genetically engineered human cells, supplies them with nutrients from the...
Algorae Pharmaceuticals Expands AI Drug Combination Pipeline with Multi-Anchor AOS2 Program
Algorae Pharmaceuticals announced the completion of the prediction‑generation phase of its multi‑anchor drug‑combination program, leveraging the AlgoraeOS v2 (AOS2) AI platform. The effort produced in‑silico synergy forecasts for 18 anchor drugs across thousands of approved and investigational compounds, covering more...
AI-Driven Wearable Patches Help Identify Undetected Hormone Disruption in Unexplained Infertility
Researchers unveiled an AI‑enabled wearable skin patch that continuously monitors reproductive hormone levels and rhythms, revealing hidden endocrine disruptions in both men and women. In a study of 102 men with normal morning testosterone, the patch detected abnormal testosterone patterns...
ALCAT1 Inhibition Restores Mitochondria, Reverses Cardiac Remodeling
Scientists at a research center in Sophia Antipolis, France, showed that pharmacological inhibition of the ALCAT1 enzyme with the compound Dafaglitapin restores mitochondrial function and reverses pressure‑overload cardiac remodeling in pre‑clinical models. The finding opens a new therapeutic pathway for...
Tecomet and Orchid Orthopedic Solutions Merge to Form Global MedTech Manufacturing Platform
Tecomet and Orchid Orthopedic Solutions have finalized a cross‑border merger, creating a unified global manufacturing platform for orthopedic devices. The deal, announced today, combines Tecomet’s European production base with Orchid’s North American footprint, positioning the new entity as a major...
WHO Launches Three‑year Digital Health Wallet Partnership to Standardize Vaccine Records
The World Health Organization announced a three‑year partnership with the Alliance for Health Policy and Systems Research and Temasek Foundation to pilot interoperable digital health wallets in selected ASEAN nations. The effort aligns with the amended International Health Regulations that,...
Ontario Audit Finds AI Scribes Hallucinate Conditions, Raising Safety Concerns
Ontario’s auditor general has flagged AI‑driven medical scribe platforms for fabricating diagnoses during testing, warning that the errors could jeopardize patient care. The report covers 20 approved vendors used by roughly 5,000 physicians, sparking a debate over regulatory oversight and...
Subjecting AI to Human Doctor Standards?
Flinders University researchers argue that AI models matching or outperforming physicians on text‑based diagnostic tasks should be judged by real‑world patient outcomes rather than benchmark scores. A recent *Science* study demonstrated AI’s parity with doctors on clinical vignettes and emergency‑department...
Hong Kong's eHealth Push Reaches Seniors, but App Use Lags
Hong Kong has enrolled 94% of its senior population—about 1.68 million people—in the citywide eHealth system, yet fewer than half (46%) have downloaded and activated the eHealth mobile app. The government responded with a new “Lite Mode” interface, on‑site support stations,...
AI Tool in Radiotherapy Advances Global Fight to Eradicate Cervical Cancer
A collaborative consortium has launched an AI‑driven radiotherapy planning platform that automates contouring and dose‑optimization for cervical cancer. Trained on more than 10,000 patient scans, the tool generates treatment plans in minutes, cutting planning time by roughly 40% while preserving...
AI Tool for Radiotherapy Can Support the Global Effort to Eliminate Cervical Cancer
An AI‑driven radiotherapy planning tool demonstrated high‑quality results in the multinational ARCHERY trial, achieving over 95% success for cervical cancer and 85% for prostate cancer. The technology compresses planning from weeks to roughly one hour, directly addressing specialist shortages that...
Intervention Improves Quality of Life in Young Adults with Cancer
A randomized trial of the Bright IDEAS‑YA program showed that six one‑on‑one problem‑solving sessions reduced depression and anxiety and improved health‑related quality of life among 344 young adults with cancer. At six months, participants experienced statistically significant gains of 3.23...
Campaigners Threaten Legal Action over UK-US Deal on Prices NHS Pays for Drugs
Campaign groups Global Justice Now and Just Treatment are threatening a judicial review after the UK government introduced a statutory instrument that allows the health secretary to over‑rule NICE’s drug‑pricing recommendations. The move is part of a broader UK‑US medicines...
STAT+: U.K. Advocacy Groups Threaten Court Action over a Key Provision in the Pharma Trade Deal with the U.S.
The United Kingdom and United States finalized a pharma‑trade agreement that grants the U.K. tariff‑free access to the U.S. market for at least three years. In exchange, Britain pledged to raise its medicines spending to 0.35% of GDP by 2028...
Moderna Began Developing a Bundibugyo Ebola mRNA “Vaccine” Just 4 Months Before WHO Declared a Global Emergency
In January 2026, CEPI granted $26.7 million to Moderna and the University of Oxford to start mRNA and viral‑vector vaccine work against the Bundibugyo ebolavirus as part of a multivalent filovirus platform. Four months later, the WHO declared a Public Health...
Weight-Loss Drugs Tied to Lower Death, Recurrence Risk After Breast Cancer
A retrospective cohort study of more than 840,000 breast‑cancer patients diagnosed between 2006 and 2023 found that use of GLP‑1 receptor agonists—drugs approved for type‑2 diabetes and obesity—was associated with a lower risk of death and cancer recurrence over a...
CMS Deploys AI‑Powered Prior Authorization Platform in Six States to Accelerate Medicare Approvals
The Centers for Medicare & Medicaid Services (CMS) has launched an AI‑assisted prior‑authorization platform across Texas, Ohio, Arizona, Oklahoma, New Jersey and Washington. The pilot, dubbed WISeR, targets high‑cost procedures and promises faster decisions, but critics warn it could increase...
Alpha Cognition Posts 40% Q1 Revenue Jump, Expands Field Team
Alpha Cognition (NASDAQ:ACOG) announced a 40% sequential increase in Q1 2026 revenue to $3.5 million, driven by expanding prescriber adoption of its Alzheimer’s drug ZUNVEYL. The company also completed a 60‑person customer‑facing field team, signaling a push to accelerate market penetration.
UC San Diego Study Links Teen Cannabis Use to Persistent Cognitive Deficits
Researchers at UC San Diego analyzed seven years of data from the Adolescent Brain Cognitive Development (ABCD) study and found that teens who use cannabis show slower growth in verbal memory, attention and processing speed. The findings, based on hair‑based...
The Government Plans to Tighten NDIS Eligibility. Here’s What’s Likely to Change
Australia's government is set to tighten eligibility for the National Disability Insurance Scheme (NDIS) through legislation introduced by Health Minister Mark Butler. The bill grants the minister authority to cut funding across entire support categories, replaces medical‑diagnosis eligibility with a...
Denali Therapeutics Secures FDA Approval for AVLAYAH, First Gene Therapy for Hunter Syndrome
Denali Therapeutics announced that the FDA granted accelerated approval to AVLAYAH, the first gene‑therapy targeting the neurologic manifestations of Hunter syndrome. The company said early commercial activity is already exceeding its launch forecasts, signaling strong physician and payer interest in...
Zusduri Demonstrates Real-World Efficacy for Low-Grade UTUC
UroGen’s Zusduri shows strong real-world results for low-grade upper tract urothelial cancer, matching clinical trial efficacy. A promising kidney-sparing option, though durability and reimbursement remain key hurdles. Urology
Mitochondria‐Targeted Zwitterionic Nanogels Trigger Photopyroptosis for Enhanced Cancer Therapy
Researchers have engineered zwitterionic PODMMA nanogels that naturally home to mitochondria, eliminating the need for additional targeting ligands. When loaded with the photosensitizer temoporfin, the nanogels deliver the drug directly to mitochondrial membranes and, upon 640 nm laser activation, generate a...
Toscafund Pitches $1.35 Bn Buyout of UK Hospital Chain Spire Healthcare
Toscafund Asset Management, Spire Healthcare’s second‑largest shareholder, has tabled a £1 bn ($1.35 bn) cash offer to acquire the private‑hospital operator. The proposal sent Spire’s shares soaring more than 40% and triggered a board recommendation that it would endorse a formal bid.
Global Consensus Renames PCOS to PMOS, Aiming for Better Diagnosis
An international panel of endocrinologists, patient groups and researchers announced that polycystic ovary syndrome will now be called polyendocrine metabolic ovarian syndrome (PMOS). The change, codified in a Lancet consensus paper after a decade‑long process involving more than 22,000 participants,...
New Study Explores Erectile Dysfunction Risk Associated With Low-Dose Finasteride Use
Researchers presented at the 2026 American Urological Association meeting a large propensity‑matched cohort study of more than 10,000 men aged 18‑45 that links low‑dose (1 mg) finasteride, commonly prescribed for androgenetic alopecia, to a higher incidence of new‑onset erectile dysfunction at...
Vaginal Birth After Cesarean More Common at Black-Serving Hospitals
A UCLA-led analysis of 1.7 million low‑risk deliveries (2017‑19) found that hospitals serving large Black populations are more likely to offer and achieve vaginal birth after cesarean (VBAC). Patients at high Black‑serving hospitals attempted labor 25% more often and succeeded about...
Targeted Radiotherapy May Delay Progression in Metastatic Breast Cancer Patients
A small randomized trial presented at ESTRO 2026 found that adding stereotactic body radiotherapy (SBRT) to standard systemic therapy significantly extended progression‑free survival in patients with oligometastatic breast cancer. Median PFS rose to 36.2 months with SBRT versus 20.6 months...
MOH, A-GC to Refine Legal Aspects of Nicotine Exemption Case
Malaysia's Health Ministry announced it will meet with the Attorney‑General's Chambers to fine‑tune the legal response after the Kuala Lumpur High Court granted a judicial review of the 2023 exemption that removed liquid nicotine and nicotine gel from the Poisons...
Just Two Radiotherapy Sessions Over Eight Days Effectively Treat Prostate Cancer Without Additional Side Effects
Researchers at the ESTRO 2026 Congress reported that a two‑session, MRI‑guided radiotherapy regimen over eight days matches the safety and efficacy of the conventional five‑session schedule for localized prostate cancer. The HERMES randomized trial involving 46 patients showed comparable toxicity, urinary...
NHS Trials Hypnotherapy for Obese Children After 13-Year-Old Drops Body Fat by 11%
The NHS’s Complications of Excess Weight service piloted clinical hypnotherapy on a 13‑year‑old boy who had not responded to conventional weight‑loss programs. After three 50‑minute hypnosis sessions and four months of self‑hypnosis, his body‑fat percentage fell from 66% to 55%,...
Text Message Reminders Improve CRC Screening in FQHCs, With Best Results at 3-Week Frequency
A quality‑improvement study of 4,822 patients at two Texas and California FQHC networks found that text‑message reminders boosted colorectal cancer (CRC) screening rates. Weekly SMS reminders over three weeks raised overall screening completion to 28% versus 24% in the control...
The Hidden Cost of Slow Cyber Remediation in Healthcare
Healthcare ransomware incidents are rising as hospitals struggle with slow vulnerability remediation. Nearly 90% of organizations run exploitable systems, and compliance timelines lag behind attacker speed. Governance layers, manual approvals, and siloed ownership extend exposure windows, prompting insurers and regulators...
What Contracting with Epic for an EHR License Really Involves: License Structure, Module Pricing, Affiliate Rights, Hosting, Termination Economics, and...
Epic’s EHR License and Support Agreement is widely regarded as the most one‑sided contract in healthcare IT. The agreement outlines a tiered license structure, per‑module pricing, strict affiliate rights, mandatory hosting on Epic’s cloud, and steep termination penalties. Because Epic...
FDA Authorizes Lenire® Device, Expanding Non‑Invasive Treatment for Chronic Tinnitus
The Tinnitus & Hearing Center of Arizona announced that Lenire®, a bimodal neuromodulation system, received FDA authorization as a non‑invasive treatment for chronic tinnitus. The device combines sound and tongue stimulation to retrain neural pathways, providing a drug‑free alternative for...
Re: NHS Maternity Care: The System Generates Demand It Cannot Meet
UK obstetricians acknowledge that NHS maternity services face mounting pressure from rising caesarean and induction rates, workforce shortages, and burdensome electronic record systems. They argue that many caesareans are planned and that higher induction rates reflect older, higher‑BMI mothers and...
HealthSplash Founder Convicted in $1 Billion Medicare Fraud Scheme
A federal jury in Florida convicted Brett Blackman, the founder of HealthSplash, of orchestrating a scheme that billed Medicare more than $1 billion for unnecessary medical equipment. The verdict underscores growing scrutiny of telemedicine platforms and durable medical equipment (DME) fraud.
Patient Involvement Transforms Modern Clinical Research
The article highlights a growing shift in clinical research from treating patients as passive subjects to engaging them as active partners. It distinguishes three levels—participation, engagement, and involvement—showing how deeper involvement lets patients shape study design and outcomes. The piece...
Re: Nicotine Pouches: WHO Calls for Stricter Regulation as Tobacco Industry Targets Young People
The World Health Organization has called for stricter regulation of nicotine pouches, warning that the tobacco industry is targeting young consumers with discreet, low‑cost products. A parallel is drawn to South Asia, where cheap single‑use sachets of pan masala and...
A Revolutionary Cancer Treatment Could Transform Autoimmune Disease
Researchers are expanding CAR T cell therapy, originally a cancer breakthrough, to treat autoimmune diseases such as multiple sclerosis, lupus, and stiff‑person syndrome. Early trials, including a 2025 Nebraska study and a 2025 Kyverna trial of 26 stiff‑person patients, report functional...
One Clinic Tracks the Heavy Toll Trump's Immigration Crackdown Takes on Mental Health
Data from Zócalo Health, a Los Angeles clinic serving Medicaid‑insured Latino families, shows a sharp increase in anxiety, depression and suicidal thoughts since the Trump administration intensified immigration raids in 2025. More than half of screened patients report severe anxiety,...
Postpartum Deaths Surge: U.S. Lacks Home Care Support
60 percent of maternal deaths happen after a woman gives birth. The U.S. system sends mothers home from delivery and schedules the next appointment six weeks later. In those six weeks, a mother manages a healing body, a newborn, often...
Obesity Consensus Calls for Dietitian‑Led Care as GLP‑1 Drugs Reshape Treatment
The European Association for the Study of Obesity, the European Federation of the Associations of Dietitians and the European Collation for Patients with Obesity released a consensus statement at ECO 2026 in Istanbul. It recommends dietitian‑led medical nutrition therapy alongside...
Ipsen's Corabotase Shows 66% Improvement in Glabellar Lines and 82% Patient Satisfaction
Ipsen presented Phase II data for its recombinant neuroinhibitor corabotase at the Scale Symposium, reporting a 66% composite response at week 4 and a 60.8% sustained effect at week 24 in moderate‑to‑severe glabellar lines. Patient satisfaction reached 82.8%, positioning the drug as...
Regeneron’s Phase 3 Melanoma Trial Misses PFS Goal, Shows 5‑Month Numeric Gain
Regeneron Pharmaceuticals reported that its Phase 3 trial of fianlimab (LAG‑3 inhibitor) combined with cemiplimab (PD‑1 inhibitor) did not achieve statistical significance for progression‑free survival versus pembrolizumab, despite a 5.1‑month median PFS advantage. The data reshape expectations for LAG‑3‑targeted regimens...
Wes Streeting, Palantir and the Corporate Capture of the NHS
Health Secretary Wes Streeting quit the cabinet and hinted at a leadership bid, while his resignation letter downplayed a controversial relationship with former Labour minister Peter Mandelson. Leaked WhatsApp exchanges show Mandelson advising Streeting on pharma policy and encouraging ties...